[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 57, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 67, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 69, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 677758, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 36, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 47, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Jacobson", "title": "Chief Legal Officer & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 56, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 18.97, "open": 19.01, "dayLow": 17.82, "dayHigh": 19.04, "regularMarketPreviousClose": 18.97, "regularMarketOpen": 19.01, "regularMarketDayLow": 17.82, "regularMarketDayHigh": 19.04, "forwardPE": -10.344828, "volume": 200940, "regularMarketVolume": 200940, "averageVolume": 293992, "averageVolume10days": 186380, "averageDailyVolume10Day": 186380, "bid": 17.87, "ask": 18.09, "bidSize": 100, "askSize": 100, "marketCap": 1620277248, "fiftyTwoWeekLow": 8.64, "fiftyTwoWeekHigh": 26.35, "priceToSalesTrailing12Months": 218.24855, "fiftyDayAverage": 17.1558, "twoHundredDayAverage": 19.364925, "currency": "USD", "enterpriseValue": 1190130432, "floatShares": 33890782, "sharesOutstanding": 90015400, "sharesShort": 548709, "sharesShortPriorMonth": 422468, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0061000003, "heldPercentInsiders": 0.00261, "heldPercentInstitutions": 0.86061996, "shortRatio": 2.12, "shortPercentOfFloat": 0.010299999, "bookValue": 4.304, "priceToBook": 4.182156, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -229402000, "trailingEps": -2.62, "forwardEps": -1.74, "enterpriseToRevenue": 160.309, "enterpriseToEbitda": -5.705, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NAMS", "underlyingSymbol": "NAMS", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "firstTradeDateEpochUtc": 1612881000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "eaa26311-e3c9-331e-9693-8ad0dbaf89e6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 18.0, "targetHighPrice": 45.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.0, "targetMedianPrice": 36.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 430708000, "totalCashPerShare": 4.785, "ebitda": -208628000, "totalDebt": 562000, "quickRatio": 9.626, "currentRatio": 9.83, "totalRevenue": 7424000, "debtToEquity": 0.145, "revenuePerShare": 0.085, "returnOnAssets": -0.27145, "returnOnEquity": -0.54077, "freeCashflow": -108423160, "operatingCashflow": -188631008, "revenueGrowth": 0.327, "grossMargins": 1.0, "operatingMargins": -23.06933, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]